Bachem Holding AG (FRA:BHM) ROCE % : 12.22% (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Bachem Holding AG ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Bachem Holding AG's annualized ROCE % for the quarter that ended in Dec. 2024 was 12.22%.

Bachem Holding AG ROCE % Historical Data

The historical data trend for Bachem Holding AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bachem Holding AG ROCE % Chart

Bachem Holding AG Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

16.45

15.36

9.66

9.26

8.60

Bachem Holding AG Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
ROCE %	Get a 7-Day Free Trial															12.30	5.89	12.58	5.32	12.22

Bachem Holding AG ROCE % Calculation

Bachem Holding AG's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	144.877	/	( ( (1784.46 - 174.663)	+	(2059.71 - 300.97) )	/ 2 )
	=	144.877	/	( (1609.797	+	1758.74)	/ 2 )
	=	144.877	/	1684.2685
	=	8.60 %

Bachem Holding AG's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Jun. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Jun. 2024 )		(Q: Dec. 2024 )
	=	202.83	/	( ( (1789.005 - 227.55)	+	(2059.71 - 300.97) )	/ 2 )
	=	202.83	/	( ( 1561.455	+	1758.74 )	/ 2 )
	=	202.83	/	1660.0975
	=	12.22 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2024) EBIT data.

Bachem Holding AG (FRA:BHM) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Bachem Holding AG ROCE % Related Terms

Thank you for viewing the detailed overview of Bachem Holding AG's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Bachem Holding AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Bachem Holding AG (FRA:BHM) » Definitions » ROCE %

Traded in Other Exchanges

BCHMY:USA BCHMF:USA BANBz:UK 0QND:UK BANB:Switzerland

Address

Hauptstrasse 144, Bubendorf, CHE, 4416

Website

https://www.bachem.com

Bachem Holding AG is a biochemical company that provides services to the pharmaceutical and biotechnology industry. It focuses on specializing in the development and manufacture of peptides and oligonucleotides. The group markets its products under the Bachem and Clinalfa brands. It has two geographic segments Europe/Asia and North America. Its products and services are CMC Development, Commercial API, Research and Specialities, and Services and Capabilities.